SUMMIT RISE Study of Acute Ischemic Stroke Patients

NCT07436156 · tracked via the Priya Life Science USA tracker

Sponsor

Route 92 Medical, Inc

Phase

Phase 4

Started

2026-02-12

Last updated

2026-02-27

Condition(s) studied

Acute Ischemic Stroke

Investigational drug(s) / intervention(s)

Route 92 Medical Reperfusion Systems

Route 92 Medical Reperfusion Systems: Mechanical thrombectomy with the Route 92 Medical Reperfusion Systems

Study summary

SUMMIT RISE Study of Acute Ischemic Stroke Patients

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Acute ischemic stroke patient initially treated (first pass) with a Route 92 Medical Reperfusion System * Informed consent completed and documented within 72 hours following thrombectomy procedure * Endovascular treatment initiated (defined as time of groin puncture) within 8 hours from time last known well * Age ≥ 18 years Exclusion Criteria: * None

Primary outcome measure(s)

Periprocedural eTICI measurement of revascularization — Periprocedural
Revascularization status checklist

Trial sites (1)

Facility	City	Region	Status
Route 92 Medical, Inc.	West Jordan	Utah	Recruiting

Other trials for the same condition

A Phase 1b Study to Assess the Safety and Tolerability of AB126 Neural Exosomes in Patients With Moderate to Severe Acute Ischemic Stroke Starting soon

Safety and Efficacy of J147 in Acute Ischemic Stroke Recruiting

Optimizing Reperfusion to Improve Outcomes and Neurologic Function Recruiting

REal-world Clinical evAulation of Medtronic NeurOVascular Products for Acute Ischemic Stroke (RECANOVA Registry) Recruiting

A Study of TAK-755 in Adults With Acute Ischemic Stroke Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07436156 on ClinicalTrials.gov ↗ ← All trials in the USA